130 related articles for article (PubMed ID: 31313392)
1. Tropomodulin 3 modulates EGFR-PI3K-AKT signaling to drive hepatocellular carcinoma metastasis.
Zheng H; Yang Y; Hong YG; Wang MC; Yuan SX; Wang ZG; Bi FR; Hao LQ; Yan HL; Zhou WP
Mol Carcinog; 2019 Oct; 58(10):1897-1907. PubMed ID: 31313392
[TBL] [Abstract][Full Text] [Related]
2. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
3. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.
Ma XL; Shen MN; Hu B; Wang BL; Yang WJ; Lv LH; Wang H; Zhou Y; Jin AL; Sun YF; Zhang CY; Qiu SJ; Pan BS; Zhou J; Fan J; Yang XR; Guo W
J Hematol Oncol; 2019 Apr; 12(1):37. PubMed ID: 30971294
[TBL] [Abstract][Full Text] [Related]
4. Tropomodulin 3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway.
Jin C; Chen Z; Shi W; Lian Q
Oncol Rep; 2019 May; 41(5):3060-3068. PubMed ID: 30864730
[TBL] [Abstract][Full Text] [Related]
5. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients.
Wang RY; Chen L; Chen HY; Hu L; Li L; Sun HY; Jiang F; Zhao J; Liu GM; Tang J; Chen CY; Yang YC; Chang YX; Liu H; Zhang J; Yang Y; Huang G; Shen F; Wu MC; Zhou WP; Wang HY
Gastroenterology; 2013 Dec; 145(6):1436-48.e1-12. PubMed ID: 23933603
[TBL] [Abstract][Full Text] [Related]
6. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
7. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
8. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.
Zhangyuan G; Wang F; Zhang H; Jiang R; Tao X; Yu D; Jin K; Yu W; Liu Y; Yin Y; Shen J; Xu Q; Zhang W; Sun B
Oncogene; 2020 Feb; 39(6):1213-1230. PubMed ID: 31605014
[TBL] [Abstract][Full Text] [Related]
9. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
10. LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
Luo Q; Wang C; Jin G; Gu D; Wang N; Song J; Jin H; Hu F; Zhang Y; Ge T; Huo X; Chu W; Shu H; Fang J; Yao M; Gu J; Cong W; Qin W
Carcinogenesis; 2015 Oct; 36(10):1201-12. PubMed ID: 26249360
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
[TBL] [Abstract][Full Text] [Related]
13. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
[TBL] [Abstract][Full Text] [Related]
14. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
15. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway.
Yao Y; Dou C; Lu Z; Zheng X; Liu Q
Cell Physiol Biochem; 2015; 35(3):983-96. PubMed ID: 25660117
[TBL] [Abstract][Full Text] [Related]
16. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
Liu C; Peng X; Li Y; Liu S; Hou R; Zhang Y; Zuo S; Liu Z; Luo R; Li L; Fang W
Biomed Pharmacother; 2020 Mar; 123():109780. PubMed ID: 31901550
[TBL] [Abstract][Full Text] [Related]
17. β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma.
Lu Y; Li X; Liu H; Xue J; Zeng Z; Dong X; Zhang T; Wu G; Yang K; Xu S
Oncogene; 2021 Feb; 40(7):1269-1283. PubMed ID: 33420362
[TBL] [Abstract][Full Text] [Related]
18. TRIM11 Upregulation Contributes to Proliferation, Invasion, and EMT of Hepatocellular Carcinoma Cells.
Zhang Z; Xu C; Zhang X; Huang L; Zheng C; Chen H; Wang Y; Ju H; Yao Q
Oncol Res; 2017 May; 25(5):691-699. PubMed ID: 28244856
[TBL] [Abstract][Full Text] [Related]
19. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Wang H; Xu L; Zhu X; Wang P; Chi H; Meng Z
Oncol Rep; 2014 Oct; 32(4):1465-72. PubMed ID: 25070581
[TBL] [Abstract][Full Text] [Related]
20. Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma.
Fu SJ; Shen SL; Li SQ; Hua YP; Hu WJ; Guo B; Peng BG
BMC Cancer; 2018 Aug; 18(1):815. PubMed ID: 30103712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
